4 - Novo Integrated Sciences, Inc. (0001138978) (Issuer)
3 - Novo Integrated Sciences, Inc. (0001138978) (Issuer)
4 - Novo Integrated Sciences, Inc. (0001138978) (Issuer)
4 - Novo Integrated Sciences, Inc. (0001138978) (Issuer)
4 - Novo Integrated Sciences, Inc. (0001138978) (Issuer)
4 - Novo Integrated Sciences, Inc. (0001138978) (Issuer)
4 - Novo Integrated Sciences, Inc. (0001138978) (Issuer)
3 - Novo Integrated Sciences, Inc. (0001138978) (Issuer)
4 - Novo Integrated Sciences, Inc. (0001138978) (Issuer)
8-K - Novo Integrated Sciences, Inc. (0001138978) (Filer)
8-K - Novo Integrated Sciences, Inc. (0001138978) (Filer)
8-K - Novo Integrated Sciences, Inc. (0001138978) (Filer)
8-K - Novo Integrated Sciences, Inc. (0001138978) (Filer)
8-K - Novo Integrated Sciences, Inc. (0001138978) (Filer)
8-K - Novo Integrated Sciences, Inc. (0001138978) (Filer)
8-K - Novo Integrated Sciences, Inc. (0001138978) (Filer)
8-K - Novo Integrated Sciences, Inc. (0001138978) (Filer)
10-Q - Novo Integrated Sciences, Inc. (0001138978) (Filer)
8-K - Novo Integrated Sciences, Inc. (0001138978) (Filer)
Dr. Joseph M. Chalil, MD, MBA, FACHE Appointed Chief Medical Officer and the New President of Novomerica Health Group Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo"), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation, today announced the Company has completed the acquisition of Clinical Consultants International LLC ("CCI"), a global consulting firm, based in Boca Raton, Florida, specializing in providing value-added services for the pharmaceutical, biotech, healthcare management, hospital management, medical marketing and strategic planning, health policy, and medic
Iodine, an essential nutrient, when in aerosolized aqueous form can be safely ingested to kill bacteria and deactivate various viruses Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo"), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation, announced today it has acquired 91% of Terragenx and the intellectual property portfolio for the unique formulation and manufacturing capability to produce a water-soluble iodine micro-nutrient that is FDA and Health Canada approved for over-the-counter and e-commerce distribution (the "Iodine IP and Patents"). Iodine is a naturally oc
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announced today Novo Healthnet Limited, a wholly owned subsidiary of the Company ("NHL"), completed the acquisition of Acenzia Inc., a Windsor Canada based company that provides nutraceutical health solutions through advanced bio-science research and development, proprietary manufacturing, and personalized diagnostics. The all-share transaction, which closed on June 24, 2021, is valued at $14,884,039, or $3.91 per share, and is subject to purchase price adjustment within 90 days of the closing date pending completion of an audit and working capital requirement provisions. Robert Mattacchione, Novo's Chairman and CEO, st
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announced today it has completed the acquisition of PRO-DIP, LLC, a U.S.-based company that has developed an innovative, patent-pending oral pouch delivery system technology which allows for broad market applications related to nutritionally focused products and medicinal based formulations. The all-share transaction is valued at $755,385, or $3.98 per share of the Company's common stock. "The acquisition of PRO-DIP is a strategically important event complimentary to one of Novo's growth initiatives to build a health science related IP portfolio," said Robert Mattacchione, Novo's Chairman and CEO. "We believe adding PRO
SC 13G/A - Novo Integrated Sciences, Inc. (0001138978) (Subject)
SC 13G/A - Novo Integrated Sciences, Inc. (0001138978) (Subject)
SC 13G - Novo Integrated Sciences, Inc. (0001138978) (Subject)
SC 13G - Novo Integrated Sciences, Inc. (0001138978) (Subject)
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announces today Mr. Robert Oliva has been appointed as the Company's new President. Mr. Oliva succeeds Mr. Christopher David, who remains as the Company's Chief Operating Officer and as a member of the Company's Board of Directors. Mr. Oliva has over 35 years of ownership and proven business development with expertise in manufacturing related operations. Mr. Oliva is expected to advance the Company's product-related operational efficiency while managing aggressive, yet sustainable growth and improving margins. Robert Mattacchione, the Company's CEO and Board Chairman, stated, "The addition of Mr. Oliva comes at a tim
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announces that Dr. Indrajit "Indra" Sinha, Ph.D. has been appointed as Novo's Chief Science Officer, effective June 24, 2021. Dr. Sinha brings over 25 years of experience in various areas of cross-disciplinary translational research, drug development, biotechnology, technology transfer, and biopharmaceutical compliance. His work has been extensively published in highly reputed peer reviewed journals. Through his passion for utilizing under-appreciated technologies and applying them in innovative ways to achieve previously unattainable outcomes, he has created various intellectual property and patents. Robert Mattacchio
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo"), today announced the Company's Board of Directors has approved an increase of up to $10 million maximum amount, from the previously announced up to $5 million maximum amount, for the repurchase of the Company's outstanding common stock from time to time in the open market at prevailing market prices or in privately negotiated transactions. The increased maximum amount available for purchase under the stock repurchase program is based on the amount, if any, of excess funds that may be generated from the pending program to monetize a Standby Letter of Credit intended to complete the Ophir Collection acquisition.
Project investment amounts expected to total $5.4 million with Acenzia investing $600 thousand, Protein Industries Canada investing $2.3 million, and two other partner companies investing $2.5 millionNovo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announced today that its wholly owned Canadian subsidiary, Acenzia Inc. ("Acenzia"), has been selected by Protein Industries Canada to participate in a new project to bring new protein products with a superior nutritional amino acid profile to the global marketplace. The total project is expected to see approximately $5.4 million invested into the development, reformulation, and commercialization of three consumer-ready prote
Gainers FibroGen (NASDAQ:FGEN) stock moved upwards by 24.4% to $1.53 during Monday's after-market session. The market value of their outstanding shares is at $152.1 million. Candel Therapeutics (NASDAQ:CADL) stock increased by 8.12% to $9.05. The company's market cap stands at $269.2 million. RAPT Therapeutics (NASDAQ:RAPT) shares moved upwards by 7.53% to $4.28. The market value of their outstanding shares is at $149.3 million. Gritstone Bio (NASDAQ:GRTS) shares increased by 7.24% to $0.79. The market value of their outstanding shares is at $85.4 million. Scholar Rock Holding (NASDAQ:SRRK) shares rose 6.96% to $10.14. The company's market cap stands at $808.7 million. Novo Integrated
Gainers Liquidia (NASDAQ:LQDA) stock rose 12.7% to $14.5 during Friday's after-market session. The market value of their outstanding shares is at $1.1 billion. Adagene (NASDAQ:ADAG) shares moved upwards by 10.67% to $2.8. The company's market cap stands at $123.6 million. Atara Biotherapeutics (NASDAQ:ATRA) stock moved upwards by 6.95% to $0.6. The market value of their outstanding shares is at $72.2 million. Novo Integrated Sciences (NASDAQ:NVOS) shares increased by 6.64% to $1.12. The company's market cap stands at $21.3 million. IGC Pharma (AMEX:IGC) stock increased by 5.95% to $0.52. The company's market cap stands at $38.8 million. Calidi Biotherapeutics (AMEX:CLDI) shares increas
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index gaining around 250 points on Friday. The Dow traded up 0.66% to 38,361.37 while the NASDAQ dipped 1.30% to 16,519.04. The S&P 500 also fell, dropping, 0.36% to 5,216.72. Check This Out: Cirrus Logic, Texas Roadhouse And 2 Other Stocks Insiders Are Selling Leading and Lagging SectorsEnergy shares rose by 2% on Friday. In trading on Friday, information technology shares fell by 1.5%. Top Headline The total number of active U.S. oil rigs slipped by 1 to 496 rigs this week, Baker Hughes Inc reported. Equities Trading UP Novo Integrated Sciences, Inc. (NASDAQ:NVOS) shares
Shares of SentinelOne, Inc. (NYSE:S) shares fell sharply during Friday's session after the company posted mixed first-quarter results. SentinelOne reported quarterly losses of 23 cents per share, which missed the analyst consensus estimate of losses of 5 cents by 360%. Quarterly sales came in at $186.4 million which beat the analyst consensus estimate of $181.09 million by 2.93%, according to data from Benzinga Pro. SentinelOne shares dipped 15.9% to $16.35 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Novo Integrated Sciences, Inc. (NASDAQ:NVOS) shares jumped 130.6% to $1.04 after the company approved a $5 million stock repurchase. The comp
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) shares are trading higher Friday after the company announced its board is conducting a review to determine whether it is appropriate to increase the company's stock repurchase program. The Details: Novo announced the board of directors is conducting a strategic review to determine whether it is appropriate to increase the maximum amount that can be repurchased pursuant to the stock repurchase program based on the amount, if any, of excess funds that may be generated from the recently disclosed program to monetize a Standby Letter of Credit intended to complete the Ophir Collection acquisition. Pending receipt of funds from the unsecured
Gainers Novo Integrated Sciences (NASDAQ:NVOS) shares rose 120.0% to $0.99 during Friday's regular session. The company's market cap stands at $18.9 million. Anebulo Pharmaceuticals (NASDAQ:ANEB) shares increased by 33.33% to $2.8. The company's market cap stands at $72.6 million. Annovis Bio (NYSE:ANVS) stock increased by 21.33% to $7.28. The market value of their outstanding shares is at $81.3 million. Vaccinex (NASDAQ:VCNX) stock increased by 20.96% to $6.29. The market value of their outstanding shares is at $9.9 million. Genprex (NASDAQ:GNPX) stock moved upwards by 19.42% to $2.89. The company's market cap stands at $6.0 million. Purple Biotech (NASDAQ:PPBT) shares moved upwards b
U.S. stocks traded mostly lower midway through trading, with the Nasdaq Composite falling around 1.5% on Friday. The Dow traded up 0.09% to 38,144.50 while the NASDAQ dipped 1.53% to 16,480.34. The S&P 500 also rose, gaining, 0.69% to 5,199.39. Check This Out: Cirrus Logic, Texas Roadhouse And 2 Other Stocks Insiders Are Selling Leading and Lagging SectorsReal estate shares rose by 1.1% on Friday. In trading on Friday, information technology shares fell by 1.3%. Top Headline The Federal Reserve's preferred inflation measure held steady in April, aligning with economist expectations, yet keeping investors anxious about potential rate cuts. The headline PCE inflation rate
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announced today that it has received confirmation of the issuance of a Standby Letter of Credit ("SBLC") by HSBC for delivery by Swift MT760, as part of a program designed for monetizing SBLCs. As previously reported, the Company entered into an application for the monetizing program whereby the Company is projected to receive gross funding proceeds of approximately $78 million under the SBLC upon completion of monetization. The Company expects to use the proceeds to close the acquisition of the Ophir Collection which will result in the sole unfettered ownership of the Ophir Collection by the Company. "The issuance o
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo"), today announced the Company's Board of Directors has approved an increase of up to $10 million maximum amount, from the previously announced up to $5 million maximum amount, for the repurchase of the Company's outstanding common stock from time to time in the open market at prevailing market prices or in privately negotiated transactions. The increased maximum amount available for purchase under the stock repurchase program is based on the amount, if any, of excess funds that may be generated from the pending program to monetize a Standby Letter of Credit intended to complete the Ophir Collection acquisition. Pending
Project investment amounts expected to total $5.4 million with Acenzia investing $600 thousand, Protein Industries Canada investing $2.3 million, and two other partner companies investing $2.5 million Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announced today that its wholly owned Canadian subsidiary, Acenzia Inc. ("Acenzia"), has been selected by Protein Industries Canada to participate in a new project to bring new protein products with a superior nutritional amino acid profile to the global marketplace. The total project is expected to see approximately $5.4 million invested into the development, reformulation, and commercialization of three consumer-ready p
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announced today the Company and RC Consulting Consortium Group LLC, in favor of SCP Tourbillion Monaco ("RC"), have amended the prepayment terms and conditions of the previously disclosed $70,000,000 promissory note, dated April 26, 2023 (the "RC Note") to provide that, at any time after 12 months and no later than 60 months from the commencement of the term of the RC Note and prior to an event of default, if the Company's listed common stock closes over $15 per share for a period of five consecutive trading days, the Company may prepay up to 50% of the outstanding RC Note in restricted shares, at a value equal to 15% gr
As previously reported, the Board of Directors (the "Board") of Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") approved the repurchase of up to $5 million of the Company's outstanding common stock from time to time in the open market at prevailing market prices or in privately negotiated transactions (the "Stock Repurchase Program"). The Company today announced that the Board is conducting a strategic review to determine whether it is appropriate to increase the maximum amount that can be repurchased pursuant to the Stock Repurchase Program based on the amount, if any, of excess funds that may be generated from the recently disclosed program to monetize a Standby Let
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announced today that as part of a program to monetize a Standby Letter of Credit ("SBLC"), the Company has received written confirmation that a Ready, Willing and Able ("RWA") has been issued by HSBC, for delivery by Swift MT 760, of a SBLC. The Company previously entered into an application for the monetizing program whereby the Company is projected to receive gross funding proceeds of approximately $78 million, under the SBLC instrument, on or before June 14, 2024. The intended use of the proceeds will secure the closing of the previously disclosed Purchase and Sale Agreement to acquire the Ophir Collection resulting
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo"), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, today reported its financial results for the second fiscal quarter ended February 29, 2024. Robert Mattacchione, Novo's CEO and Board Chairman, stated, "The Company's fiscal year 2024 second quarter period emphasized maximizing operational efficiencies pointed towards future cost savings and margin improvement. The Company continues to work with certain prospective financial partners to close previously announced non-tradi
Both the Mast Hill $3,500,000 Note and the FirstFire $277,777 Note were Paid in Full with Cash Proceeds from the Streeterville Note Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announced today the Company has entered into a securities purchase agreement, dated April 5, 2024, with Streeterville Capital, LLC ("Streeterville") pursuant to which the Company issued a secured convertible promissory note (the "Note") with a maturity date of April 8, 2025 in the principal sum of $6,210,000. On April 8, 2024, Streeterville paid the purchase price of $5,500,000 in exchange for the Note. On April 10, 2024, the Company repaid in full the remaining outstanding balances for bo
WEST PALM BEACH, Fla., April 11, 2024 /PRNewswire/ -- Anthony, Linder & Cacomanolis, PLLC is proud to announce that Partner Craig D. Linder has been selected to the 2024 Top 50 Lawyers in America list for securities law. This prestigious accolade is part of the 10th annual list honoring a select group of 50 lawyers who have demonstrated outstanding leadership and success within the securities law community in the Americas. America's Top 50 Lawyers identifies and highlights the accomplishments of the nation's most distinguished and skilled attorneys in all fields of practice of law. Only 50 lawyers in each state will receive this honor and be selected for this esteemed membership. This hon
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo"), today provides an update with respect to certain actions and events, as follows: Purchase and Sale Agreement – Ophir Collection: As previously disclosed, on November 21, 2023 Novo entered into a Purchase and Sale Agreement ("Ophir Agreement") between the Company and Blake Alsbrook, solely in his capacity as Court-appointed successor receiver (the "Successor Receiver") in Ocean Thermal Energy Corporation v. C. Robert Coe II, et al., United States District Court for the Central District of California (the "Court") Case No. 2:19-cv-04299 VAP (JPRx) to acquire a certain collection of 43 gemstones, 42 of which are certifi
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction | (Commission | (IRS Employer | ||
of Incorporation) | File Number) | Identification Number) |
(Address of principal executive offices)
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.)
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CF$ 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class | Trading Symbol(s) | Name of Each Exchange on which Registered | ||
The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 28, 2023 (the “Effective Date”), Novo Integrated Sciences, Inc., a Nevada corporation (the “Company”) entered into a separation and general release agreement (the “Agreement”) with Jim Zsebok (“Zsebok”) and RTZ Consulting Group, Inc. (“RTZ”, and collectively with Zsebok, the “Zsebok Parties”), an entity owned by Zsebok. Pursuant to the terms of the Agreement, all independent contract relationships between the Company and the Zsebok Parties were terminated, and Zsebok resigned from the position of principal financial officer with respect to the Company. The Company issued to RTZ (i) 1,000,000 shares of the Company’s common stock pursuant to the Company’s 2021 Equity Incentive Plan and (ii) 335,000 unregistered shares of the Company’s common stock for the full satisfaction of the Company’s obligations to the Zsebok Parties in connection with such termination and resignation. The Agreement contains customary representations, warranties, and covenants, including, among other things and subject to certain exceptions, confidentiality and non-disparagement provisions.
The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. | Description | |
10.1 | Separation and General Release Agreement, dated as of June 28, 2023, by and between Novo Integrated Sciences, Inc., Jim Zsebok, and RTZ Consulting Group, Inc. | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Novo Integrated Sciences, Inc. | ||
Dated: July 3, 2023 | By: | /s/ Christopher David |
Christopher David | ||
President |